Z-Ligustilide
(Synonyms: 藁本内酯) 目录号 : GN10567
A phthalide with diverse biological activities
Cas No.:81944-09-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 2.27 and 4.78 μM against L1210 and K562 cell lines
Z-Ligustilide, isolated and purified from the essential oil of A. sinensis. Z-Ligustilide has been reported to facilitate blood circulation and attenuate inflammatory pain behavior.
In vitro: Previous results showed pretreatment with Z-Ligustilide (LIG) improved cell viability significantly. The apoptosis rate in glutamate-induced PC12 cells decreased in the presence of LIG. Western blot results indicated that LIG could decrease the release of Cyt C from mitochondria, up-regulate Bcl-2/Bax ratio and down-regulate Caspase-3 protein expression, resulting in protecting PC12 cells from apoptosis [1].
In vivo: In ovariectomized (OVX) osteopenic rats, the anti-inflammatory potential of LIG was determined by ELISA. LIG was found to be able to inhibit OVX-induced up-regulation of NF-κB activation and the production of TNF-α, iNOS, IL-1β, ICAM-1 and COX-2 significantly. In addition, LIG could suppress MDA and PMN infiltration. The significant anti-inflammatory effect of Z-Ligustilide in experimental OVX osteopenic rats clearly demonstrated that there might be an inflammatory component in the etiology of osteoporosis [2].
Clinical trial: N/A
References:
[1] Wu Q,Wang N,Wang Y,Wang GY,Piao XX. rotective effect of ligustilide against glutamate-induced apoptosis in PC12 cells. Yao Xue Xue Bao.2015 Feb;50(2):162-8.
[2] Ma Z,Bai L. The anti-inflammatory effect of Z-Ligustilide in experimental ovariectomized osteopenic rats. Inflammation.2012 Dec;35(6):1793-7.
| Cas No. | 81944-09-4 | SDF | |
| 别名 | 藁本内酯 | ||
| 化学名 | (3Z)-3-butylidene-4,5-dihydro-2-benzofuran-1-one | ||
| Canonical SMILES | CCCC=C1C2=C(C=CCC2)C(=O)O1 | ||
| 分子式 | C12H14O2 | 分子量 | 190.23 |
| 溶解度 | ≥ 16.45mg/mL in DMSO | 储存条件 | -20°C, protect from light, stored under nitrogen |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 5.2568 mL | 26.284 mL | 52.5679 mL |
| 5 mM | 1.0514 mL | 5.2568 mL | 10.5136 mL |
| 10 mM | 0.5257 mL | 2.6284 mL | 5.2568 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。